Abstract
Autologous Active Specific Immunotherapy (AASI) is a type of immunotherapy that targets complementary autoantibodies which suppress the specific immune response using anti-idiotypic antibodies. AASI entails removing immune cells (dendritic cells) from the patient's blood and subjecting them in a lab setting to a particular tumour antigen (proteins detected on the surface of cancer cells). AASI is a personalized treatment approach that has been used to treat various types of cancer, including melanoma, osteosarcoma and breast cancer. Clinical trials have shown promising results, with some patients experiencing complete remission or long-term disease control. Although AASI has shown potential as a cancer treatment, further research is needed to optimize its effectiveness and safety. AASI is a complex and expensive therapy, and its use is currently limited to specialized cancer treatment centres.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Vaccines & Vaccination
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
